Xanadu Bio
Privately held biotechnology company developing a biodegradable poly(amine-co-ester) polymer nanoparticle delivery platform for mRNA, self-amplifying RNA, and other nucleic acids. The platform is described as tunable for organ- and cell-specific delivery, formulated for systemic or intranasal administration, and being applied to vaccine boosters and therapeutic indications in oncology and immunology. The company pursues academic licensing and industry collaborations to advance preclinical and translational programs.
Industries
Nr. of Employees
small (1-50)
Xanadu Bio
Gladwyne, Pennsylvania, United States, North America
Products
Polymeric nanoparticle delivery platform (poly(amine-co-ester) family)
A tunable, biodegradable polymer nanoparticle platform designed to encapsulate and protect nucleic acids and be formulated for systemic or intranasal administration; engineered for organ and cell targeting and scalable manufacture.
Intranasal mRNA vaccine booster programs
Development programs for intranasal boosters intended to induce mucosal immunity in the nasosinus/upper respiratory tract to reduce infection and transmission of respiratory viruses.
PACE Platform
A next generation polymer nanoparticle delivery platform that allows for specific and efficient delivery of nucleic acids, including mRNA and saRNA. It is fully biodegradable, easily manufactured, cost effective, scalable, and can be functionalized for organ and cell specific delivery. Formulated for safe systemic or intranasal delivery.
Polymeric nanoparticle delivery platform (poly(amine-co-ester) family)
A tunable, biodegradable polymer nanoparticle platform designed to encapsulate and protect nucleic acids and be formulated for systemic or intranasal administration; engineered for organ and cell targeting and scalable manufacture.
Intranasal mRNA vaccine booster programs
Development programs for intranasal boosters intended to induce mucosal immunity in the nasosinus/upper respiratory tract to reduce infection and transmission of respiratory viruses.
PACE Platform
A next generation polymer nanoparticle delivery platform that allows for specific and efficient delivery of nucleic acids, including mRNA and saRNA. It is fully biodegradable, easily manufactured, cost effective, scalable, and can be functionalized for organ and cell specific delivery. Formulated for safe systemic or intranasal delivery.
Services
Licensing of the poly(amine-co-ester) polymer delivery platform and collaborative evaluation of platform applications with industry or academic partners.
Licensing of the poly(amine-co-ester) polymer delivery platform and collaborative evaluation of platform applications with industry or academic partners.
Expertise Areas
- Nucleic acid delivery
- Polymeric nanoparticle design
- Intranasal and mucosal vaccine development
- Biodegradable biomaterials
Key Technologies
- Poly(amine-co-ester) biodegradable polymer nanoparticles
- mRNA and self-amplifying RNA (saRNA) delivery
- Intranasal/mucosal delivery
- Organ- and cell-specific functionalization of nanoparticles
News & Updates
Press announcement describing an agreement to evaluate the poly(amine-co-ester) polymer nanoparticle platform with a pharmaceutical company for potential drug development applications.
Peer-reviewed article reporting polymer nanoparticle delivery of mRNA to the lung for mucosal vaccination (Science Translational Medicine, 2023).
Peer-reviewed article reporting intranasal spike protein vaccine eliciting mucosal immunity (Science, 2022).
Press release describing exclusive license agreement from Yale University for a next-generation polymeric nanoparticle delivery platform and options for intranasal vaccine boosters.
Press announcement describing an agreement to evaluate the poly(amine-co-ester) polymer nanoparticle platform with a pharmaceutical company for potential drug development applications.
Peer-reviewed article reporting polymer nanoparticle delivery of mRNA to the lung for mucosal vaccination (Science Translational Medicine, 2023).
Peer-reviewed article reporting intranasal spike protein vaccine eliciting mucosal immunity (Science, 2022).
Press release describing exclusive license agreement from Yale University for a next-generation polymeric nanoparticle delivery platform and options for intranasal vaccine boosters.